Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
26
OTLC Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
-0.41%
Day range:
$0.07 - $0.09
52-week range:
$0.02 - $0.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.91x
Volume:
331.5K
Avg. volume:
181.9K
1-year change:
171.05%
Market cap:
$35.4M
Revenue:
--
EPS (TTM):
-$0.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OTLC
Oncotelic Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.18% | 79.14% | $209.29 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 31.31% | 54.16% | $1,093.22 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.84% | 39.23% | $110.04 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OTLC
Oncotelic Therapeutics, Inc.
|
$0.08 | -- | $35.4M | -- | $0.00 | 0% | -- |
|
JNJ
Johnson & Johnson
|
$207.63 | $209.29 | $500.2B | 20.04x | $1.30 | 2.48% | 5.46x |
|
LLY
Eli Lilly & Co.
|
$1,077.75 | $1,093.22 | $964.6B | 53.30x | $1.50 | 0.56% | 16.54x |
|
MRK
Merck & Co., Inc.
|
$106.78 | $110.04 | $265B | 14.13x | $0.85 | 3.07% | 4.21x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
PFE
Pfizer Inc.
|
$25.09 | $28.62 | $142.7B | 14.62x | $0.43 | 6.86% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OTLC
Oncotelic Therapeutics, Inc.
|
61.64% | -3.780 | 44.25% | 0.02x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OTLC
Oncotelic Therapeutics, Inc.
|
-- | -$491K | -8.93% | -25.13% | -- | -$307K |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Oncotelic Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns OTLC or JNJ?
Johnson & Johnson has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 21.47%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About OTLC or JNJ?
Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4902.5%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Oncotelic Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings OTLCOncotelic Therapeutics, Inc.0 0 0 JNJJohnson & Johnson9 11 0 -
Is OTLC or JNJ More Risky?
Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock OTLC or JNJ?
Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OTLC or JNJ?
Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Johnson & Johnson's net income of $5.2B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M JNJJohnson & Johnson5.46x 20.04x $24B $5.2B
-
Which has Higher Returns OTLC or LLY?
Eli Lilly & Co. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 31.72%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About OTLC or LLY?
Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4902.5%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings OTLCOncotelic Therapeutics, Inc.0 0 0 LLYEli Lilly & Co.18 7 0 -
Is OTLC or LLY More Risky?
Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock OTLC or LLY?
Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OTLC or LLY?
Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M LLYEli Lilly & Co.16.54x 53.30x $17.6B $5.6B
-
Which has Higher Returns OTLC or MRK?
Merck & Co., Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 33.68%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About OTLC or MRK?
Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4902.5%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLCOncotelic Therapeutics, Inc.0 0 0 MRKMerck & Co., Inc.15 12 0 -
Is OTLC or MRK More Risky?
Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock OTLC or MRK?
Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OTLC or MRK?
Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M MRKMerck & Co., Inc.4.21x 14.13x $17.2B $5.8B
-
Which has Higher Returns OTLC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of -255.85%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About OTLC or NBY?
Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4902.5%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLCOncotelic Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is OTLC or NBY More Risky?
Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock OTLC or NBY?
Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLC or NBY?
Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns OTLC or PFE?
Pfizer Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 21.32%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About OTLC or PFE?
Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4902.5%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLCOncotelic Therapeutics, Inc.0 0 0 PFEPfizer Inc.7 15 1 -
Is OTLC or PFE More Risky?
Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock OTLC or PFE?
Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios OTLC or PFE?
Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M PFEPfizer Inc.2.28x 14.62x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
